Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
The development of T-cell-based immunotherapies of cancer largely depends on the availability of tumour-associated antigens capable of eliciting tumour-directed cytotoxic T-cell responses. In prostate cancer, the number of antigens defined as suitable targets of cytotoxic T lymphocytes (CTLs) is still limited. Recently, prostein was identified as a transmembrane protein that is highly restricted to prostate tissues. In our study, prostein transcripts were found to be abundant in both malignant and nonmalignant prostate tissue samples. To identify immunogenic CD8+ T-cell epitopes, human leucocyte antigen-A*0201-binding peptides were selected from the amino-acid sequence of prostein and were used for the in vitro stimulation of CD8+ T lymphocytes. Specific CTLs were raised against the prostein-derived peptide CLAAGITYV that were capable of lysing prostate cancer cells, indicating that this peptide is naturally generated by tumour cells. Our data suggest that prostein is a suitable candidate to be included in a T-cell-based immunotherapy of prostate cancer.
Details
Original language | English |
---|---|
Pages (from-to) | 1034-1040 |
Number of pages | 7 |
Journal | British journal of cancer |
Volume | 90 |
Issue number | 5 |
Publication status | Published - 8 Mar 2004 |
Peer-reviewed | Yes |
External IDs
PubMed | 14997204 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Dendritic cells, Immunotherapy, Prostein, T cells, Tumour antigen